Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer (LiverMWA1)

University Hospital, Gasthuisberg

Status: Completed

Conditions: Liver Neoplasms

Treatments: Device: Radiofrequency ablation; Device: Microwave ablation

Study type: Interventional

Funder types: Other

Identifiers

NCT00922181

kulasMWA1

Details and patient eligibility

About

Microwave ablation (MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate the variability and reproducibility of single-probe MWA versus radiofrequency ablation (RFA) of metastatic liver tumours smaller than 3 cm in patients without underlying liver disease.

Enrollment: 19 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Unresectable metastatic liver cancer
• No invasion of major biliary structures
• No invasion of major vascular structures
• ASA score < 4
• WHO score 0-1
• Pre-operative chemotherapy is allowed

Exclusion criteria

• Resectable liver metastases
• Life expectancy less than 3 months
• Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic instruments or other metal materials
• Coagulopathy with platelet count less than 50000
• Active infectious disease
• Age below 18 years
• Pregnancy of breastfeeding

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

19 participants in 2 patient groups

MWA

Experimental group

Description:

Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease

Treatment:

Device: Microwave ablation

RFA

Active Comparator group

Description:

Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease

Treatment:

Device: Radiofrequency ablation